400 related articles for article (PubMed ID: 22367781)
21. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists.
Mandawat A; Fiskus W; Buckley KM; Robbins K; Rao R; Balusu R; Navenot JM; Wang ZX; Ustun C; Chong DG; Atadja P; Fujii N; Peiper SC; Bhalla K
Blood; 2010 Dec; 116(24):5306-15. PubMed ID: 20810927
[TBL] [Abstract][Full Text] [Related]
22. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
[TBL] [Abstract][Full Text] [Related]
23. Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling.
Wang L; Syn NL; Subhash VV; Any Y; Thuya WL; Cheow ESH; Kong L; Yu F; Peethala PC; Wong AL; Laljibhai HJ; Chinnathambi A; Ong PS; Ho PC; Sethi G; Yong WP; Goh BC
Cancer Lett; 2018 Mar; 417():152-160. PubMed ID: 29306016
[TBL] [Abstract][Full Text] [Related]
24. Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer.
Kou X; Jiang X; Liu H; Wang X; Sun F; Han J; Fan J; Feng G; Lin Z; Jiang L; Yang Y
Cancer Sci; 2018 Oct; 109(10):3272-3284. PubMed ID: 30039622
[TBL] [Abstract][Full Text] [Related]
25. PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells.
Qin Y; Zhao X; Fang Y
Int J Gynecol Cancer; 2014 Oct; 24(8):1373-80. PubMed ID: 25188886
[TBL] [Abstract][Full Text] [Related]
26. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
Fiskus W; Ren Y; Mohapatra A; Bali P; Mandawat A; Rao R; Herger B; Yang Y; Atadja P; Wu J; Bhalla K
Clin Cancer Res; 2007 Aug; 13(16):4882-90. PubMed ID: 17699868
[TBL] [Abstract][Full Text] [Related]
27. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
[TBL] [Abstract][Full Text] [Related]
28. Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells.
Rao R; Nalluri S; Kolhe R; Yang Y; Fiskus W; Chen J; Ha K; Buckley KM; Balusu R; Coothankandaswamy V; Joshi A; Atadja P; Bhalla KN
Mol Cancer Ther; 2010 Apr; 9(4):942-52. PubMed ID: 20371724
[TBL] [Abstract][Full Text] [Related]
29. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.
Ellis L; Ku SY; Ramakrishnan S; Lasorsa E; Azabdaftari G; Godoy A; Pili R
Oncotarget; 2013 Dec; 4(12):2225-36. PubMed ID: 24163230
[TBL] [Abstract][Full Text] [Related]
30. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
[TBL] [Abstract][Full Text] [Related]
31. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Fiskus W; Rao R; Fernandez P; Herger B; Yang Y; Chen J; Kolhe R; Mandawat A; Wang Y; Joshi R; Eaton K; Lee P; Atadja P; Peiper S; Bhalla K
Blood; 2008 Oct; 112(7):2896-905. PubMed ID: 18660379
[TBL] [Abstract][Full Text] [Related]
32. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Imai Y; Ohta E; Takeda S; Sunamura S; Ishibashi M; Tamura H; Wang YH; Deguchi A; Tanaka J; Maru Y; Motoji T
JCI Insight; 2016 Apr; 1(5):e85061. PubMed ID: 27699258
[TBL] [Abstract][Full Text] [Related]
34. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition.
Giommarelli C; Zuco V; Favini E; Pisano C; Dal Piaz F; De Tommasi N; Zunino F
Cell Mol Life Sci; 2010 Mar; 67(6):995-1004. PubMed ID: 20039095
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
[TBL] [Abstract][Full Text] [Related]
36. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
37. The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression.
Gahr S; Mayr C; Kiesslich T; Illig R; Neureiter D; Alinger B; Ganslmayer M; Wissniowski T; Fazio PD; Montalbano R; Ficker JH; Ocker M; Quint K
Int J Oncol; 2015 Sep; 47(3):963-70. PubMed ID: 26202945
[TBL] [Abstract][Full Text] [Related]
38. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
39. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
[TBL] [Abstract][Full Text] [Related]
40. A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer.
Wu YH; Hong CW; Wang YC; Huang WJ; Yeh YL; Wang BJ; Wang YJ; Chiu HW
Cancer Lett; 2017 Aug; 400():79-88. PubMed ID: 28450160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
